Click here to get full coverage on Behavioral Patterns of CSTL and Institutional Flows - Stock Traders Daily

Behavioral Patterns of CSTL and Institutional Flows  Stock Traders Daily

Behavioral Patterns of CSTL and Institutional Flows - Stock Traders Daily

Click here to get full coverage on How Investors Are Reacting To Castle Biosciences (CSTL) Upgraded 2025 Revenue Outlook And Test Volume Growth - simplywall.st

How Investors Are Reacting To Castle Biosciences (CSTL) Upgraded 2025 Revenue Outlook And Test Volume Growth  simplywall.st

How Investors Are Reacting To Castle Biosciences (CSTL) Upgraded 2025 Revenue Outlook And Test Volume Growth - simplywall.st

Click here to get full coverage on Castle Biosciences (CSTL) Valuation After Upgraded Guidance And Higher Analyst Growth Expectations - Sahm

Castle Biosciences (CSTL) Valuation After Upgraded Guidance And Higher Analyst Growth Expectations  Sahm

Castle Biosciences (CSTL) Valuation After Upgraded Guidance And Higher Analyst Growth Expectations - Sahm

Click here to get full coverage on Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth - Yahoo Finance

Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth  Yahoo Finance

Castle Biosciences (CSTL) Valuation After Upgraded 2025 Guidance And Strong Core Test Volume Growth - Yahoo Finance

Click here to get full coverage on Noteworthy Thursday Option Activity: CSTL, MOD, UBER - Nasdaq

Noteworthy Thursday Option Activity: CSTL, MOD, UBER  Nasdaq

Noteworthy Thursday Option Activity: CSTL, MOD, UBER - Nasdaq

Click here to get full coverage on $CSTL stock is up 20% today. Here's what we see in our data. - Quiver Quantitative

$CSTL stock is up 20% today. Here's what we see in our data.  Quiver Quantitative

$CSTL stock is up 20% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $50 - 富途资讯

CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $50  富途资讯

CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $50 - 富途资讯

Click here to get full coverage on Castle Biosciences (CSTL) Sees PT Raised by Lake Street: Analyst Insights | CSTL Stock News - GuruFocus

Castle Biosciences (CSTL) Sees PT Raised by Lake Street: Analyst Insights | CSTL Stock News  GuruFocus

Castle Biosciences (CSTL) Sees PT Raised by Lake Street: Analyst Insights | CSTL Stock News - GuruFocus

Click here to get full coverage on The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook - Yahoo Finance

The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook  Yahoo Finance

The Bull Case For Castle Biosciences (CSTL) Could Change Following Surging Test Volumes And Raised 2025 Outlook - Yahoo Finance

Click here to get full coverage on How Investors May Respond To Castle Biosciences (CSTL) Raising 2025 Revenue Outlook On Strong Test Demand - Sahm

How Investors May Respond To Castle Biosciences (CSTL) Raising 2025 Revenue Outlook On Strong Test Demand  Sahm

How Investors May Respond To Castle Biosciences (CSTL) Raising 2025 Revenue Outlook On Strong Test Demand - Sahm

Click here to get full coverage on Guggenheim Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $43 - 富途资讯

Guggenheim Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $43  富途资讯

Guggenheim Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $43 - 富途资讯

Click here to get full coverage on Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable - Nasdaq

Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable  Nasdaq

Castle Biosciences (CSTL) is on the Move, Here's Why the Trend Could be Sustainable - Nasdaq

Click here to get full coverage on Castle Biosciences Inc (CSTL) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance

Castle Biosciences Inc (CSTL) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ...  Yahoo Finance

Castle Biosciences Inc (CSTL) Q3 2025 Earnings Call Highlights: Revenue Growth and Strategic ... - Yahoo Finance

Click here to get full coverage on Castle Biosciences Inc (CSTL) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Castle Biosciences Inc (CSTL) Q3 2025 Earnings Report Preview: What To Expect  Yahoo Finance

Castle Biosciences Inc (CSTL) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Click here to get full coverage on What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' - Yahoo Finance

What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'  Yahoo Finance

What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing' - Yahoo Finance

Click here to get full coverage on Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up - simplywall.st

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up  simplywall.st

Castle Biosciences, Inc.'s (NASDAQ:CSTL) 44% Share Price Surge Not Quite Adding Up - simplywall.st

Click here to get full coverage on Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance

Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates  Yahoo Finance

Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates - Yahoo Finance

Click here to get full coverage on Castle Biosciences (CSTL) Expects 2025 Revenue to Surpass $340 M - GuruFocus

Castle Biosciences (CSTL) Expects 2025 Revenue to Surpass $340 M  GuruFocus

Castle Biosciences (CSTL) Expects 2025 Revenue to Surpass $340 M - GuruFocus

Click here to get full coverage on $CSTL stock is up 33% today. Here's what we see in our data. - Quiver Quantitative

$CSTL stock is up 33% today. Here's what we see in our data.  Quiver Quantitative

$CSTL stock is up 33% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Castle Biosciences (CSTL): Losses Narrow 9.6% Yearly, Profitability Challenges Weigh on Slow Revenue Growth - Yahoo Finance

Castle Biosciences (CSTL): Losses Narrow 9.6% Yearly, Profitability Challenges Weigh on Slow Revenue Growth  Yahoo Finance

Castle Biosciences (CSTL): Losses Narrow 9.6% Yearly, Profitability Challenges Weigh on Slow Revenue Growth - Yahoo Finance

Click here to get full coverage on Castle Biosciences (CSTL) Is Up 6.5% After New Melanoma Data Validates DecisionDx Tests - simplywall.st

Castle Biosciences (CSTL) Is Up 6.5% After New Melanoma Data Validates DecisionDx Tests  simplywall.st

Castle Biosciences (CSTL) Is Up 6.5% After New Melanoma Data Validates DecisionDx Tests - simplywall.st

Click here to get full coverage on Oelschlager, Castle Biosciences COO, sells $390k in CSTL stock - Investing.com

Oelschlager, Castle Biosciences COO, sells $390k in CSTL stock  Investing.com

Oelschlager, Castle Biosciences COO, sells $390k in CSTL stock - Investing.com

Click here to get full coverage on Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $52 - 富途资讯

Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $52  富途资讯

Lake Street Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $52 - 富途资讯

Click here to get full coverage on Castle Biosciences (NASDAQ:CSTL) shareholders have endured a 58% loss from investing in the stock five years ago - Yahoo Finance

Castle Biosciences (NASDAQ:CSTL) shareholders have endured a 58% loss from investing in the stock five years ago  Yahoo Finance

Castle Biosciences (NASDAQ:CSTL) shareholders have endured a 58% loss from investing in the stock five years ago - Yahoo Finance

Click here to get full coverage on What Makes Castle Biosciences (CSTL) a New Strong Buy Stock - Nasdaq

What Makes Castle Biosciences (CSTL) a New Strong Buy Stock  Nasdaq

What Makes Castle Biosciences (CSTL) a New Strong Buy Stock - Nasdaq

Click here to get full coverage on Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results - GlobeNewswire

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results  GlobeNewswire

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results - GlobeNewswire

Click here to get full coverage on Castle Biosciences (CSTL) Awards Restricted Stock Units to New E - GuruFocus

Castle Biosciences (CSTL) Awards Restricted Stock Units to New E  GuruFocus

Castle Biosciences (CSTL) Awards Restricted Stock Units to New E - GuruFocus

Click here to get full coverage on Castle Biosciences 2025 Total Revenue Expected To Exceed $340 Million - TradingView — Track All Markets

Castle Biosciences 2025 Total Revenue Expected To Exceed $340 Million  TradingView — Track All Markets

Castle Biosciences 2025 Total Revenue Expected To Exceed $340 Million - TradingView — Track All Markets

Click here to get full coverage on Castle Bio (NASDAQ: CSTL) shows five-year MSS 98.5% vs 82.3% in nodular melanoma - Stock Titan

Castle Bio (NASDAQ: CSTL) shows five-year MSS 98.5% vs 82.3% in nodular melanoma  Stock Titan

Castle Bio (NASDAQ: CSTL) shows five-year MSS 98.5% vs 82.3% in nodular melanoma - Stock Titan

Click here to get full coverage on Castle Biosciences (Nasdaq: CSTL) Receives 13 Top Workplaces and Culture Excellence Honors - Stock Titan

Castle Biosciences (Nasdaq: CSTL) Receives 13 Top Workplaces and Culture Excellence Honors  Stock Titan

Castle Biosciences (Nasdaq: CSTL) Receives 13 Top Workplaces and Culture Excellence Honors - Stock Titan

Click here to get full coverage on Castle Biosciences (Nasdaq: CSTL) launches AdvanceAD-Tx; EASI-90 45.5% vs 8.3% with JAKi - Stock Titan

Castle Biosciences (Nasdaq: CSTL) launches AdvanceAD-Tx; EASI-90 45.5% vs 8.3% with JAKi  Stock Titan

Castle Biosciences (Nasdaq: CSTL) launches AdvanceAD-Tx; EASI-90 45.5% vs 8.3% with JAKi - Stock Titan

Click here to get full coverage on Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 58% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews

Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 58% Potential Upside with Strong Buy Ratings  DirectorsTalk Interviews

Castle Biosciences, Inc. (CSTL) Stock Analysis: Exploring a 58% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews

Click here to get full coverage on Castle Biosciences, Inc. to Announce Third Quarter 2025 Financial Results on November 3 - Quiver Quantitative

Castle Biosciences, Inc. to Announce Third Quarter 2025 Financial Results on November 3  Quiver Quantitative

Castle Biosciences, Inc. to Announce Third Quarter 2025 Financial Results on November 3 - Quiver Quantitative

Click here to get full coverage on Autumnal adventures - massapequapost.com

Autumnal adventures  massapequapost.com

Autumnal adventures - massapequapost.com

Click here to get full coverage on Castle Biosciences Scheduled to Present at Stephens 27th Annual Investment Conference and Jefferies Global Healthcare Conference - Quiver Quantitative

Castle Biosciences Scheduled to Present at Stephens 27th Annual Investment Conference and Jefferies Global Healthcare Conference  Quiver Quantitative

Castle Biosciences Scheduled to Present at Stephens 27th Annual Investment Conference and Jefferies Global Healthcare Conference - Quiver Quantitative

Click here to get full coverage on Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? - Yahoo Finance

Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)?  Yahoo Finance

Does New Melanoma Data Redefine the Bull Case for Castle Biosciences' DecisionDx Platform (CSTL)? - Yahoo Finance

Click here to get full coverage on Castle Biosciences (NASDAQ: CSTL) to present Dec. 2; live webcast and replay available - Stock Titan

Castle Biosciences (NASDAQ: CSTL) to present Dec. 2; live webcast and replay available  Stock Titan

Castle Biosciences (NASDAQ: CSTL) to present Dec. 2; live webcast and replay available - Stock Titan

Click here to get full coverage on CSTL's Price Target Raised to $50 by BTIG Analyst Mark Massaro | - GuruFocus

CSTL's Price Target Raised to $50 by BTIG Analyst Mark Massaro |  GuruFocus

CSTL's Price Target Raised to $50 by BTIG Analyst Mark Massaro | - GuruFocus

Click here to get full coverage on Castle Biosciences to Release Third Quarter 2025 Financial - GlobeNewswire

Castle Biosciences to Release Third Quarter 2025 Financial  GlobeNewswire

Castle Biosciences to Release Third Quarter 2025 Financial - GlobeNewswire

Click here to get full coverage on Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)  GlobeNewswire

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Click here to get full coverage on Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential (NASDAQ:CSTL) - Seeking Alpha

Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential (NASDAQ:CSTL)  Seeking Alpha

Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential (NASDAQ:CSTL) - Seeking Alpha

Click here to get full coverage on Diagnostic Testing Leader Castle Biosciences Secures 9th Workplace Award in 2025, Including Pittsburgh Honor - Stock Titan

Diagnostic Testing Leader Castle Biosciences Secures 9th Workplace Award in 2025, Including Pittsburgh Honor  Stock Titan

Diagnostic Testing Leader Castle Biosciences Secures 9th Workplace Award in 2025, Including Pittsburgh Honor - Stock Titan

Click here to get full coverage on What is the fair value of CSTL stock now - Chart Signals & Reliable Breakout Forecasts - ulpravda.ru

What is the fair value of CSTL stock now - Chart Signals & Reliable Breakout Forecasts  ulpravda.ru

What is the fair value of CSTL stock now - Chart Signals & Reliable Breakout Forecasts - ulpravda.ru

Click here to get full coverage on Castle Biosciences Stock Surges 19% After Q3 Results And Guidance Raise - Nasdaq

Castle Biosciences Stock Surges 19% After Q3 Results And Guidance Raise  Nasdaq

Castle Biosciences Stock Surges 19% After Q3 Results And Guidance Raise - Nasdaq

Click here to get full coverage on Earnings call transcript: Castle Biosciences Q3 2025 beats revenue forecast - Investing.com

Earnings call transcript: Castle Biosciences Q3 2025 beats revenue forecast  Investing.com

Earnings call transcript: Castle Biosciences Q3 2025 beats revenue forecast - Investing.com

Click here to get full coverage on Castle Biosciences Reports Strong Preliminary 2025 Revenue Growth - TipRanks

Castle Biosciences Reports Strong Preliminary 2025 Revenue Growth  TipRanks

Castle Biosciences Reports Strong Preliminary 2025 Revenue Growth - TipRanks

Click here to get full coverage on Castle Biosciences (NASDAQ:CSTL Investor Five-year Losses Grow to 59% as the Stock Sheds US$77m This Past Week - 富途资讯

Castle Biosciences (NASDAQ:CSTL Investor Five-year Losses Grow to 59% as the Stock Sheds US$77m This Past Week  富途资讯

Castle Biosciences (NASDAQ:CSTL Investor Five-year Losses Grow to 59% as the Stock Sheds US$77m This Past Week - 富途资讯

Click here to get full coverage on Castle Biosciences stock rating reiterated at Buy by Canaccord Genuity - Investing.com Nigeria

Castle Biosciences stock rating reiterated at Buy by Canaccord Genuity  Investing.com Nigeria

Castle Biosciences stock rating reiterated at Buy by Canaccord Genuity - Investing.com Nigeria

Click here to get full coverage on Castle Biosciences CEO Maetzold sells $289k in shares - Investing.com

Castle Biosciences CEO Maetzold sells $289k in shares  Investing.com

Castle Biosciences CEO Maetzold sells $289k in shares - Investing.com

Click here to get full coverage on Kyverna Therapeutics Stock Up 41% in a Month: Here's Why - Finviz

Kyverna Therapeutics Stock Up 41% in a Month: Here's Why  Finviz

Kyverna Therapeutics Stock Up 41% in a Month: Here's Why - Finviz

Click here to get full coverage on Castle Biosciences Named to Newsweek's Inaugural America's Greatest Companies List for 2025 - Quiver Quantitative

Castle Biosciences Named to Newsweek's Inaugural America's Greatest Companies List for 2025  Quiver Quantitative

Castle Biosciences Named to Newsweek's Inaugural America's Greatest Companies List for 2025 - Quiver Quantitative

Click here to get full coverage on Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern - Seeking Alpha

Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern  Seeking Alpha

Castle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A Concern - Seeking Alpha

Click here to get full coverage on Oelschlager, Castle Biosciences COO, sells $317k in stock - Investing.com

Oelschlager, Castle Biosciences COO, sells $317k in stock  Investing.com

Oelschlager, Castle Biosciences COO, sells $317k in stock - Investing.com

Click here to get full coverage on Castle Biosciences Reports Second Quarter 2025 Results - Yahoo Finance

Castle Biosciences Reports Second Quarter 2025 Results  Yahoo Finance

Castle Biosciences Reports Second Quarter 2025 Results - Yahoo Finance

Click here to get full coverage on Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? - Finviz

Ocugen Stock Surges 75% Year to Date: What's in Store for 2026?  Finviz

Ocugen Stock Surges 75% Year to Date: What's in Store for 2026? - Finviz

Click here to get full coverage on Castle Biosciences, Inc. to Release Second Quarter Financial Results on August 4, 2025 - Quiver Quantitative

Castle Biosciences, Inc. to Release Second Quarter Financial Results on August 4, 2025  Quiver Quantitative

Castle Biosciences, Inc. to Release Second Quarter Financial Results on August 4, 2025 - Quiver Quantitative

Click here to get full coverage on Why Castle Biosciences' Rally Might Just Be Getting Started - Benzinga

Why Castle Biosciences' Rally Might Just Be Getting Started  Benzinga

Why Castle Biosciences' Rally Might Just Be Getting Started - Benzinga

Click here to get full coverage on Castle Biosciences Scores Relative Strength Rating Upgrade - Investor's Business Daily

Castle Biosciences Scores Relative Strength Rating Upgrade  Investor's Business Daily

Castle Biosciences Scores Relative Strength Rating Upgrade - Investor's Business Daily

Click here to get full coverage on Published on: 2026-01-12 11:47:21 - ulpravda.ru

Published on: 2026-01-12 11:47:21  ulpravda.ru

Published on: 2026-01-12 11:47:21 - ulpravda.ru

Click here to get full coverage on Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast - Investing.com

Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast  Investing.com

Earnings call transcript: Castle Biosciences Q2 2025 beats EPS forecast - Investing.com

Click here to get full coverage on Castle Biosciences stock rating reiterated at Buy by Canaccord Genuity - Investing.com South Africa

Castle Biosciences stock rating reiterated at Buy by Canaccord Genuity  Investing.com South Africa

Castle Biosciences stock rating reiterated at Buy by Canaccord Genuity - Investing.com South Africa

Click here to get full coverage on Castle Biosciences to Acquire Previse - GlobeNewswire

Castle Biosciences to Acquire Previse  GlobeNewswire

Castle Biosciences to Acquire Previse - GlobeNewswire

Click here to get full coverage on Castle Biosciences Announces Definitive Agreement to Acquire Previse, Enhancing Gastroenterology Offerings - Quiver Quantitative

Castle Biosciences Announces Definitive Agreement to Acquire Previse, Enhancing Gastroenterology Offerings  Quiver Quantitative

Castle Biosciences Announces Definitive Agreement to Acquire Previse, Enhancing Gastroenterology Offerings - Quiver Quantitative

Click here to get full coverage on 5 Stocks With Recent Price Strength Amid Wall Street Volatility - Zacks Investment Research

5 Stocks With Recent Price Strength Amid Wall Street Volatility  Zacks Investment Research

5 Stocks With Recent Price Strength Amid Wall Street Volatility - Zacks Investment Research

Click here to get full coverage on 4 Stocks With Recent Price Strength to Enhance Your Portfolio - Zacks Investment Research

4 Stocks With Recent Price Strength to Enhance Your Portfolio  Zacks Investment Research

4 Stocks With Recent Price Strength to Enhance Your Portfolio - Zacks Investment Research

Click here to get full coverage on Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year - GlobeNewswire

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year  GlobeNewswire

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year - GlobeNewswire

Click here to get full coverage on New Strong Sell Stocks for August 1st - TradingView — Track All Markets

New Strong Sell Stocks for August 1st  TradingView — Track All Markets

CSTL

Price Chart

Key Statistics

Technicals

About CSTL

Latest News

Behavioral Patterns of CSTL and Institutional Flows - Stock Traders Daily

How Investors Are Reacting To Castle Biosciences (CSTL) Upgraded 2025 Revenue Outlook And Test Volume Growth - simplywall.st

Castle Biosciences (CSTL) Valuation After Upgraded Guidance And Higher Analyst Growth Expectations - Sahm

Advanced Charts

Top Gainers

Top Losers